Cytokinetics, Incorporated
- Jurisdiction
United States - LEI
549300BE5DY1HW7IHA64 - ISIN
US23282W6057 (CYTK )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
4
/ 7
Profile
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. Read full profile
Fundamentals
- Net revenue
€73.13M - Gross margin
-227.0% - EBIT
-€466.55M - EBIT margin
-638.0% - Net income
-€517.15M - Net margin
-707.2%
Statement period: - (published )
Estimates
| Fiscal Year | Net revenue | Net income |
|---|---|---|
|
|
| |
|
|
| |
|
|
|
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
| Name | Title | Transaction Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Blum Robert I | President & CEO |
|
|
|
|
| Harrington Robert Arthur | N/A |
|
|
|
|
| Kaye Edward M. MD | N/A |
|
|
|
|
| Malik Fady Ibraham | EVP Research & Development |
|
|
|
|
| Blum Robert I | President & CEO |
|
|
|
|
Congress transactions
| Name | Transaction date | Value |
|---|---|---|
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
| Lisa McClain | August 13, 2025 | $1.00K–$15.00K |
Investor transactions
| Name | Shares | Value | Last change | Change type |
|---|---|---|---|---|
| Peter Brown |
|
|
|
Sell |